Two experimental heart drugs fail to reduce cardiovascular events in trials

6 SOURCES UNITED STATESUPDATED

NOT MEDICAL ADVICE

This brief summarizes public reporting and official announcements. Research findings may be preliminary. Talk to a qualified clinician before making health decisions.

BLUF

Pelacarsen lowered lipoprotein(a) but did not improve cardiovascular outcomes; a separate trial found that ziltivekimab also did not reduce cardiovascular events. Both are experimental treatments, and the reported results do not establish whether other approaches will work.

HOW THIS BRIEF WAS MADE 5 outlets: 3 national · 1 international · 1 specialist. Automated sourcing and summaries by the BLUF engine. Corrections

Why it matters

The findings may shape future research and drug development, but they do not change established treatment options based on the information provided. People with cardiovascular disease or elevated risk are affected by the research, not by a new treatment decision described here.

What happens next

The articles report the trial results but do not specify further decisions, timelines, or whether the full data have been published in a peer-reviewed journal.

Whether full trial data are published and peer-reviewed

Whether researchers test other approaches to lowering lipoprotein(a) or inflammation